Perspective Therapeutics updates oncology pipeline overview

Perspective Therapeutics, Inc. provides an updated corporate presentation describing a strategy to “redefine oncology treatment” with next‑generation radiopharmaceuticals built around the alpha‑emitting isotope 212Pb.

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. provides an updated corporate presentation describing a strategy to “redefine oncology treatment” with next‑generation radiopharmaceuticals built around the alpha‑emitting isotope 212Pb. The company emphasizes engineering the “alpha advantage,” careful isotope selection, and a theranostic approach to treating solid tumors.

The presentation outlines a direct‑to‑hospital delivery model supported by integrated isotope production and daily regional manufacturing of ready‑to‑administer products. Lead programs include VMT‑α‑NET for SSTR2+ neuroendocrine tumors, VMT01 targeting MC1R for melanoma, and PSV359 targeting FAP‑ɑ in advanced solid tumors, all in ongoing Phase 1/2a studies.

Slides reference deepening responses over time and durable disease control for VMT‑α‑NET, preliminary anti‑tumor activity and tolerability for VMT01, improved tumor retention for PSV359, and a broad intellectual‑property portfolio across the radiopharmaceutical value chain, supported by experienced leadership in radiopharmaceutical and drug development.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

VMT-α-NET patients in safety follow-up: 68 patients VMT01 dose with preliminary activity: 3.0 mCi Cycles of VMT01 before partial response: 2 cycles +1 more

4 metrics

VMT-α-NET patients in safety follow-up 68 patients Blood creatinine during follow-up for all patients treated (n=68)

VMT01 dose with preliminary activity 3.0 mCi Preliminary anti-tumor activity observed at 3.0 mCi dose of VMT01

Cycles of VMT01 before partial response 2 cycles Metastatic melanoma: confirmed partial response after 2 cycles of [212Pb]VMT01

Alpha-emitting isotope used 212Pb Programs described as 212Pb-based radioligand or radiopharmaceutical therapies

Key Terms

radiopharmaceuticals, theranostic, SSTR2+ Neuroendocrine Tumors, FAP-ɑ, +2 more

6 terms

radiopharmaceuticals medical

"Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

theranostic medical

"Advancing a Theranostic Approach"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

SSTR2+ Neuroendocrine Tumors medical

"SSTR2+ Neuroendocrine Tumors is a Large, Growing Market"

FAP-ɑ medical

"FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential"

immune check point inhibitors medical

"212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors"

Spider Plot technical

"Spider Plot of Tumor Change Over Time by Patient"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Perspective Therapeutics (CATX) update on August 3, 2026?

Perspective Therapeutics updated its corporate presentation on August 3, 2026, highlighting its 212Pb-based radiopharmaceutical strategy, solid tumor focus, and clinical pipeline, along with integrated isotope production and regional manufacturing to support direct‑to‑hospital delivery of ready‑to‑administer oncology therapies.

What is Perspective Therapeutics’ (CATX) core oncology technology?

The company focuses on next‑generation radiopharmaceuticals using the alpha‑emitting isotope 212Pb. Its strategy centers on optimizing structural chemistry, selecting appropriate isotopes, and using a theranostic approach to target and visualize solid tumors while managing systemic exposure and treatment precision.

Which lead drug candidates are highlighted in CATX’s updated presentation?

The deck highlights three main 212Pb programs: VMT‑α‑NET for SSTR2+ neuroendocrine tumors, VMT01 targeting MC1R for melanoma, and PSV359 targeting FAP‑ɑ in advanced solid tumors, each described as being in ongoing Phase 1/2a clinical trials.

How is Perspective Therapeutics (CATX) approaching radiopharmaceutical manufacturing and delivery?

Perspective Therapeutics describes a direct‑to‑hospital delivery model supported by integrated isotope production. It highlights daily production at regional manufacturing sites to ensure a consistent supply of ready‑to‑administer radiopharmaceutical product for reaching the largest addressable solid tumor markets.

What clinical signals are mentioned for VMT‑α‑NET and VMT01 in CATX’s deck?

For VMT‑α‑NET, slides reference best responses and disease control deepening over time with a best‑in‑class safety profile. For VMT01, the deck notes preliminary anti‑tumor activity at a 3.0 mCi dose and describes the therapy as well‑tolerated with initial anti‑tumor activity.

Which cancer markets does Perspective Therapeutics (CATX) target with its 212Pb portfolio?

The company targets solid tumors, including SSTR2+ neuroendocrine tumors, melanoma via MC1R targeting, and FAP‑ɑ–expressing advanced solid tumors. It characterizes solid tumors as an attractive market and emphasizes expanding the addressable market with its diverse 212Pb-based oncology portfolio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:16 PM Accepted by SEC EDGAR 08/03/2026 - 04:15 PM Learn about SEC filing dates

false000072838700007283872026-08-032026-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 03, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 3, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	August 3, 2026	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Engineering the Alpha Advantage in Targeted Oncology

Unlocking New Treatment Options Across Solid Tumors:

Optimizing the Entire System

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Optimizing Structural Chemistry:

Choosing the Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Expanding the Addressable Market

Direct-to-Hospital Delivery through Integrated Isotope Production

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Reaching the Largest Addressable Market with Regional Manufacturing

Advancing a Diverse 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-⍺-NET in NETs

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

VMT-α-NET Best Response Deepens Over Time

VMT-α-NET Responses Deepen Over Time

VMT-⍺-NET: Durable Disease Control Across All Doses

Spider Plot of Tumor Change Over Time by Patient

Best-in-class Safety Profile1

Blood Creatinine During Follow-up for All Patients Treated (n=68)

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade:

Abbreviations

APPENDIX

Deep Leadership Across Radiopharmaceutical and Drug Development

NETs Trials

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Construct designed for better clinical outcome

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 20.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.3 KB